DE69819478D1 - Verfahren zur detektion und lokalisation maligner meschlicher tumore des pankreas - Google Patents

Verfahren zur detektion und lokalisation maligner meschlicher tumore des pankreas

Info

Publication number
DE69819478D1
DE69819478D1 DE69819478T DE69819478T DE69819478D1 DE 69819478 D1 DE69819478 D1 DE 69819478D1 DE 69819478 T DE69819478 T DE 69819478T DE 69819478 T DE69819478 T DE 69819478T DE 69819478 D1 DE69819478 D1 DE 69819478D1
Authority
DE
Germany
Prior art keywords
pancreas
detecting
composition
localizing
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69819478T
Other languages
English (en)
Other versions
DE69819478T2 (de
Inventor
C Reubi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Application granted granted Critical
Publication of DE69819478D1 publication Critical patent/DE69819478D1/de
Publication of DE69819478T2 publication Critical patent/DE69819478T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/085—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being neurotensin
DE69819478T 1997-02-03 1998-02-02 Verfahren zum Nachweis und zur Lokalisierung maligner menschlicher Pankreastumore Expired - Lifetime DE69819478T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97200297 1997-02-03
EP97200297 1997-02-03
PCT/US1998/001964 WO1998033531A1 (en) 1997-02-03 1998-02-02 Method for the detection and localization of malignant human tumours

Publications (2)

Publication Number Publication Date
DE69819478D1 true DE69819478D1 (de) 2003-12-11
DE69819478T2 DE69819478T2 (de) 2004-09-02

Family

ID=26146106

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69819478T Expired - Lifetime DE69819478T2 (de) 1997-02-03 1998-02-02 Verfahren zum Nachweis und zur Lokalisierung maligner menschlicher Pankreastumore

Country Status (11)

Country Link
US (2) US6312661B1 (de)
EP (1) EP0968001B1 (de)
JP (1) JP2001511152A (de)
AT (1) ATE253381T1 (de)
AU (1) AU728712C (de)
CA (1) CA2279530C (de)
DE (1) DE69819478T2 (de)
HU (1) HUP0001316A3 (de)
IL (1) IL131386A0 (de)
NO (1) NO993846L (de)
WO (1) WO1998033531A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3340699B2 (ja) * 1998-06-05 2002-11-05 東京瓦斯株式会社 膵外分泌機能診断剤
US7232559B1 (en) 1999-06-04 2007-06-19 Tokyo Gas Company Limited Diagnostic agents for pancreatic exocrine function
AU2119101A (en) * 1999-10-22 2001-05-08 Insight Neuroimaging Systems, Llc Ligand chelated paramagnetic mri contrast agents
US7630907B2 (en) * 2001-10-30 2009-12-08 Biodose, Llc Algorithm and program for the handling and administration of radioactive pharmaceuticals
US8175890B2 (en) * 2001-10-30 2012-05-08 Biodose, Llc Pharmacy based method and algorithm for handling of radioactive pharmaceuticals and generating of reports therefrom
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
EP1587944A4 (de) 2002-03-01 2007-03-21 Dyax Corp Kdr und vegf/kdr-bindende peptide und ihre diagnostische und therapeutische veranwendung bei der diagnose und therapie
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US20040039241A1 (en) * 2002-05-29 2004-02-26 Biodose Llc Integrated distribution and communication process and algorithm for providing, handling, distributing or generating reports regarding radioactive pharmaceuticals
WO2004009614A2 (en) * 2002-07-24 2004-01-29 The Salk Institute For Biological Studies Receptor (sstr4)- selective somatostatin analogs
GR1004637B (el) * 2003-04-04 2004-07-23 Βιομεντικααλαιφασαιενσισαανωνυμηαεταιριααφαρμακευτικωναπροιοντωναα Συνθεσηαβιολογικηακαιαπροκλινικηααξιολογησηααναλογωνανευροτενσινησα}@@bατροποποιημενωναμεαπαραγωγαατουᐏ@ϊ@τετρααζαενδεκανιουα}@ϊ@tetraazaundecanebακαιαεπισημασμενωναμεατεχνητιο@mα}αηαλλααραδιονουκλιδιαατουατεχνητιουbαη@καιαρηνιο@ϊϊα}΄ηααλλααραδιονουκλιδιαατουαρηνιουbαγιααεφαρμογηαστηναογκολογιαα
WO2005027981A1 (en) * 2003-09-17 2005-03-31 Board Of Regents, The University Of Texas System Mechanism-based targeted pancreatic beta cell imaging and therapy
US7507547B2 (en) * 2004-09-09 2009-03-24 University Of Massachusetts Screening assays for antioxidants and antiproliferative compounds
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
US8586043B2 (en) 2009-01-07 2013-11-19 Inserm ( Institut National De La Sante Et De La Recherche Medicale) Methods for treating breast cancer with inhibitors of neurotensin activation of NTSR1
US9809624B2 (en) * 2009-07-16 2017-11-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors
US8378134B2 (en) 2009-09-30 2013-02-19 General Electric Company Hydroxylated contrast enhancement agents
EP2740726A1 (de) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin-Rezeptorligande
EP2954933A1 (de) 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Konjugat mit einem Neurotensinrezptorligand
WO2015188934A1 (en) 2014-06-10 2015-12-17 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954934A1 (de) 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Konjugat aus einem Neurotensinrezeptorliganden und Verwendung davon

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687680A1 (fr) * 1992-02-20 1993-08-27 Centre Nat Rech Scient Procede de marquage de proteines et de peptides par acylation de leur fonction alpha aminee par un reactif comportant une fonction carboxylique activee.
EP0636032A1 (de) * 1992-03-25 1995-02-01 Mallinckrodt Medical, Inc. Methode zur Feststellung und Lokalisierung von Tumorgeweben während einerOperation
CA2086453A1 (en) * 1992-12-30 1994-07-01 Mcgill University Marker for neurotensin receptor
DE4337599A1 (de) * 1993-11-01 1995-05-04 Diagnostikforschung Inst Metallbindende cysteinfreie Peptide für Diagnose und Therapie, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP0752873A4 (de) * 1994-02-18 2002-05-15 Mallinckrodt Inc Markierte peptidverbindungen
FR2720066B1 (fr) * 1994-05-20 1996-06-28 Rhone Poulenc Rorer Sa Peptides antagonistes de la neurotensine.
FR2722193B1 (fr) * 1994-07-08 1996-10-04 Sanofi Sa Derives n-oxydes de 1-(7-chloro-4-quinoleinyl)pyrazole-3-carboxamides substitues, procede pour leur preparation et les compositions pharmaceitiques les contenant
WO1996023527A1 (en) * 1995-02-03 1996-08-08 Mallinckrodt Medical, Inc. Method for the detection and localization of malignant human tumours

Also Published As

Publication number Publication date
JP2001511152A (ja) 2001-08-07
NO993846L (no) 1999-09-09
AU6262298A (en) 1998-08-25
US6312661B1 (en) 2001-11-06
US20020155064A1 (en) 2002-10-24
HUP0001316A2 (hu) 2000-09-28
AU728712C (en) 2001-07-19
CA2279530A1 (en) 1998-08-06
AU728712B2 (en) 2001-01-18
CA2279530C (en) 2009-04-28
IL131386A0 (en) 2001-01-28
DE69819478T2 (de) 2004-09-02
EP0968001B1 (de) 2003-11-05
WO1998033531A1 (en) 1998-08-06
HUP0001316A3 (en) 2001-10-29
NO993846D0 (no) 1999-08-10
ATE253381T1 (de) 2003-11-15
EP0968001A1 (de) 2000-01-05

Similar Documents

Publication Publication Date Title
DE69819478D1 (de) Verfahren zur detektion und lokalisation maligner meschlicher tumore des pankreas
CN101631801B (zh) 受体（sstr2）-选择性生长抑素拮抗剂
Tjuvajev et al. Iododeoxyuridine uptake and retention as a measure of tumor growth
US20110117012A1 (en) Radiolabeled gallium complexes, methods for synthesis and use for pet imaging of egfr expression in malignant tumors
Bonnet‐Duquennoy et al. Targeted radionuclide therapy of melanoma: anti‐tumoural efficacy studies of a new 131I labelled potential agent
Kahán et al. Inhibition of growth of MX‐1, MCF‐7‐MIII and MDA‐MB‐231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN‐238
Bogdanov Jr et al. Treatment of experimental brain tumors with trombospondin-1 derived peptides: an in vivo imaging study
Liu et al. 99mTc-labeled SWL specific peptide for targeting EphA2 receptor
Kim et al. Characterization, biodistribution and small-animal SPECT of I-125-labeled c-Met binding peptide in mice bearing c-Met receptor tyrosine kinase-positive tumor xenografts
N Eberle et al. Synthetic peptide drugs for targeting skin cancer: malignant melanoma and melanotic lesions
O'Byrne et al. Scintigraphic imaging of small-cell lung cancer with [111In] pentetreotide, a radiolabelled somatostatin analogue
Guo et al. A novel indium-111-labeled gonadotropin-releasing hormone peptide for human prostate cancer imaging
Nagy et al. Targeted cytotoxic somatostatin analogs: a modern approach to the therapy of various cancers
KR102396324B1 (ko) 인 시츄 면역 조절 암 백신화를 위한 표적화된 방사선요법 킬레이트
Nock et al. Theranostic perspectives in prostate cancer with the GRPR-antagonist NeoBOMB1–preclinical and first clinical results
Liu et al. In vivo imaging of human colorectal cancer using radiolabeled analogs of the uroguanylin peptide hormone
JP2022517662A (ja) 腫瘍細胞外マトリックスにおける腫瘍性タンパク質に特異的なペプチドｐｅｔ／ｓｐｅｃｔプローブ
JP2002516882A5 (de)
JP2005514335A (ja) 腫瘍イメージング及び治療のためのｐａｃａｐ組成物及び方法
WO1997031657A3 (en) Use of labelled cck-b receptor ligands for the detection and localization of malignant human tumors
US20170326166A1 (en) Compositions and methods for treating pituitary tumors
Varshney et al. Targeting Bombesin Peptide Receptors for Cancer Imaging: Perspective in Prostate, Lung and Breast Cancer
Cornelissen et al. Influence of farnesyl transferase inhibitor treatment on epidermal growth factor receptor status
US11213597B2 (en) Kinin-based theranostic probes for solid cancers and uses thereof
Kinuya et al. Short-period-induced hypertension could improve tumor-to-nontumor ratios of radiolabeled monoclonal antibody

Legal Events

Date Code Title Description
8364 No opposition during term of opposition